Gains and Amplifications of c-myc, EGFR, and 20.q13 Loci in the No Dysplasia–Dysplasia–Adenocarcinoma Sequence of Barrett's Esophagus
Open Access
- 1 June 2008
- journal article
- Published by American Association for Cancer Research (AACR) in Cancer Epidemiology, Biomarkers & Prevention
- Vol. 17 (6) , 1380-1385
- https://doi.org/10.1158/1055-9965.epi-07-2734
Abstract
The progression of Barrett's esophagus to esophageal adenocarcinoma is often characterized by the accumulation of genetic abnormalities. The goal was to evaluate the copy number alterations of several oncogene loci, including 7p12 [epidermal growth factor receptor (EGFR)], 8q24 (c-myc), and 20q13 in the sequence of no dysplasia–dysplasia–adenocarcinoma of Barrett's esophagus. Fluorescence in situ hybridization with DNA probes for the centromeric region of chromosome 7 and the locus-specific regions of 7p12 (EGFR), 8q24 (c-myc), and 20q13 was applied on 99 brush cytology specimens of patients with Barrett's esophagus with different stages of dysplasia or esophageal adenocarcinoma. Gains (3-4 copies) of chromosome 17, 8q24 (c-myc), and 20q.13 loci were found in the low frequencies in nondysplastic Barrett's esophagus. Their frequencies increased with the stage of dysplasia and reached a high incidence in esophageal adenocarcinoma. Amplification (>4 copies) of at least 1 of the loci was observed in 14% of high-grade dysplasia and increased to 50% in esophageal adenocarcinoma (P = 0.015). The most frequently amplified locus was c-myc (18%), followed by 20q13 (13%) and EGFR (11%) in the high-grade dysplasia/esophageal adenocarcinoma cases. High amplification levels (>10 copies) of the loci were more frequent in esophageal adenocarcinoma (72%) compared with high-grade dysplasia (20%; P = 0.049). Amplifications of the c-myc, EGFR, and 20q12 loci may serve as diagnostic markers to identify patients with Barrett's esophagus with high-grade dysplasia or esophageal adenocarcinoma. Gains of the loci might be of value as prognostic markers because they are already present in nondysplasia cases and may precede the later event of the amplification as observed in high-grade dysplasia and esophageal adenocarcinoma. (Cancer Epidemiol Biomarkers Prev 2008;17(6):1380–5)Keywords
This publication has 40 references indexed in Scilit:
- The Development of a Fluorescence in Situ Hybridization Assay for the Detection of Dysplasia and Adenocarcinoma in Barrett's EsophagusThe Journal of Molecular Diagnostics, 2006
- Epidermal Growth Factor Receptor in Non–Small-Cell Lung Carcinomas: Correlation Between Gene Copy Number and Protein Expression and Impact on PrognosisJournal of Clinical Oncology, 2003
- Frequent c-mycAmplification in High-Grade Dysplasia and Adenocarcinoma in Barrett EsophagusAmerican Journal of Clinical Pathology, 2001
- Chromosomal Imbalances in Barrett's Adenocarcinoma and the Metaplasia-Dysplasia-Carcinoma SequenceThe American Journal of Pathology, 2000
- Dominant genetic alterations in immortalization: Role for 20q gainGenes, Chromosomes and Cancer, 1999
- MYC oncogenes and human neoplastic diseaseOncogene, 1999
- Molecular Evolution of the Metaplasia-Dysplasia-Adenocarcinoma Sequence in the EsophagusThe American Journal of Pathology, 1999
- 20q gain associates with immortalization: 20q13.2 amplification correlates with genome instability in human papillomavirus 16 E7 transformed human uroepithelial cellsOncogene, 1997
- Prevalence of metaplasia at the gastro-oesophageal junctionThe Lancet, 1994
- Amplification and over‐expression of the EGFR and erbB‐2 genes in human esophageal adenocarcinomasInternational Journal of Cancer, 1993